• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

带有亮氨酸拉链的模块化嵌合细胞因子受体通过 JAK/STAT 信号增强 CAR T 细胞的抗肿瘤活性。

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling.

机构信息

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.

Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

Nat Biomed Eng. 2024 Apr;8(4):380-396. doi: 10.1038/s41551-023-01143-w. Epub 2023 Nov 30.

DOI:10.1038/s41551-023-01143-w
PMID:38036617
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11587785/
Abstract

The limited availability of cytokines in solid tumours hinders maintenance of the antitumour activity of chimeric antigen receptor (CAR) T cells. Cytokine receptor signalling pathways in CAR T cells can be activated by transgenic expression or injection of cytokines in the tumour, or by engineering the activation of cognate cytokine receptors. However, these strategies are constrained by toxicity arising from the activation of bystander cells, by the suboptimal biodistribution of the cytokines and by downregulation of the cognate receptor. Here we show that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provides optimal Janus kinase/signal transducer and activator of transcription signalling. Such chimeric cytokine receptors, which can be generated for common γ-chain receptors, interleukin-10 and -12 receptors, enabled T cells to survive cytokine starvation without induction of autonomous cell growth, and augmented the effector function of CAR T cells in vitro in the setting of chronic antigen exposure and in human tumour xenografts in mice. As a modular design, leucine zippers can be used to generate constitutively active cytokine receptors in effector immune cells.

摘要

实体肿瘤中细胞因子的有限可用性阻碍了嵌合抗原受体 (CAR) T 细胞抗肿瘤活性的维持。CAR T 细胞中的细胞因子受体信号通路可以通过在肿瘤中转基因表达或注射细胞因子、或通过工程化激活同源细胞因子受体来激活。然而,这些策略受到以下因素的限制:细胞因子的非最佳生物分布和同源受体下调导致的旁观者细胞激活毒性、毒性。在这里,我们表明,用两个亮氨酸拉链基序替换 T 细胞中异二聚体细胞因子受体的细胞外结构域,可提供最佳的 Janus 激酶/信号转导和转录激活因子信号。这种嵌合细胞因子受体可用于常见的 γ 链受体、白细胞介素-10 和 -12 受体,使 T 细胞能够在没有诱导自主细胞生长的情况下在细胞因子饥饿中存活,并在慢性抗原暴露的情况下增强 CAR T 细胞在体外的效应功能,并在小鼠的人肿瘤异种移植物中增强其效应功能。作为一种模块化设计,亮氨酸拉链可用于在效应免疫细胞中产生组成型激活的细胞因子受体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/89968e157361/nihms-2035781-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/14bf5952261b/nihms-2035781-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/6c40f2806d45/nihms-2035781-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/59158c633f2c/nihms-2035781-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/17b1d13dd480/nihms-2035781-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/ad84ddd6b3ec/nihms-2035781-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/92f46c01b2d7/nihms-2035781-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/b421e677c7ec/nihms-2035781-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/8c4cccdf8a16/nihms-2035781-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/0496c203eb4f/nihms-2035781-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/f8b1d82e749d/nihms-2035781-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/78a00fb70950/nihms-2035781-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/9d13c317944f/nihms-2035781-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/cf988a6c637c/nihms-2035781-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/d7049260490f/nihms-2035781-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/2a5c33c32fb3/nihms-2035781-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/89968e157361/nihms-2035781-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/14bf5952261b/nihms-2035781-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/6c40f2806d45/nihms-2035781-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/59158c633f2c/nihms-2035781-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/17b1d13dd480/nihms-2035781-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/ad84ddd6b3ec/nihms-2035781-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/92f46c01b2d7/nihms-2035781-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/b421e677c7ec/nihms-2035781-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/8c4cccdf8a16/nihms-2035781-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/0496c203eb4f/nihms-2035781-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/f8b1d82e749d/nihms-2035781-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/78a00fb70950/nihms-2035781-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/9d13c317944f/nihms-2035781-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/cf988a6c637c/nihms-2035781-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/d7049260490f/nihms-2035781-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/2a5c33c32fb3/nihms-2035781-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e26a/11587785/89968e157361/nihms-2035781-f0006.jpg

相似文献

1
Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling.带有亮氨酸拉链的模块化嵌合细胞因子受体通过 JAK/STAT 信号增强 CAR T 细胞的抗肿瘤活性。
Nat Biomed Eng. 2024 Apr;8(4):380-396. doi: 10.1038/s41551-023-01143-w. Epub 2023 Nov 30.
2
Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.嵌合细胞因子受体的开发,该受体可捕获 IL-6 并增强 CAR-T 细胞的抗肿瘤反应。
Cell Rep Med. 2024 May 21;5(5):101526. doi: 10.1016/j.xcrm.2024.101526. Epub 2024 Apr 25.
3
Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway.Cullin-5缺陷可能通过调节JAK/STAT信号通路促进嵌合抗原受体T细胞的效应功能。
Nat Commun. 2024 Dec 10;15(1):10376. doi: 10.1038/s41467-024-54794-x.
4
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.一种新型嵌合抗原受体,包含 JAK-STAT 信号域,介导优越的抗肿瘤效应。
Nat Med. 2018 Mar;24(3):352-359. doi: 10.1038/nm.4478. Epub 2018 Feb 5.
5
Interleukin-23 engineering improves CAR T cell function in solid tumors.白细胞介素-23 工程改善 CAR T 细胞在实体瘤中的功能。
Nat Biotechnol. 2020 Apr;38(4):448-459. doi: 10.1038/s41587-019-0398-2. Epub 2020 Feb 3.
6
JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.JAK/STAT 依赖性嵌合抗原受体 (CAR) 表达:一种从双与门/或门设计中受益的设计,旨在提高特异性、减少肿瘤逃逸并影响肿瘤微环境。
Front Immunol. 2021 Jun 9;12:638639. doi: 10.3389/fimmu.2021.638639. eCollection 2021.
7
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.IL-18R 支持的嵌合抗原受体 T 细胞针对癌胚 tenascin C 用于儿科肉瘤和脑肿瘤的免疫治疗。
J Immunother Cancer. 2024 Nov 20;12(11):e009743. doi: 10.1136/jitc-2024-009743.
8
Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors.基于亮氨酸拉链的展示多种受体的嵌合抗原受体T细胞的免疫磁珠纯化。
Nat Biomed Eng. 2024 Dec;8(12):1592-1614. doi: 10.1038/s41551-024-01287-3. Epub 2024 Dec 23.
9
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
10
Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.同时靶向 Tim3 和 A2a 受体可调节 MSLN-CAR T 细胞在人宫颈肿瘤异种移植模型中的抗肿瘤功能。
Front Immunol. 2024 May 24;15:1362904. doi: 10.3389/fimmu.2024.1362904. eCollection 2024.

引用本文的文献

1
A Supramolecular Self-assembly Approach to Site-Specific Antibody Conjugates a Coiled-coil Peptides Platform.一种用于位点特异性抗体偶联物的超分子自组装方法——一种卷曲螺旋肽平台。
bioRxiv. 2025 Jul 25:2025.07.21.665979. doi: 10.1101/2025.07.21.665979.
2
Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024).美国食品药品监督管理局(FDA)批准的嵌合抗原受体T细胞产品的科学研究知识图谱与文献计量分析(2015 - 2024年)
Discov Oncol. 2025 Aug 3;16(1):1461. doi: 10.1007/s12672-025-03360-y.
3
CD8GZMKCD27CCR7 T cells mobilized by splenic sympathetic nerves aggravate brain ischemia‒reperfusion injury via CCL19-positive endothelial cells.

本文引用的文献

1
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.GD2-CART01 治疗复发/难治高危神经母细胞瘤。
N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859.
2
Enhanced T cell effector activity by targeting the Mediator kinase module.靶向中介激酶模块增强 T 细胞效应器活性。
Science. 2022 Nov 11;378(6620):eabn5647. doi: 10.1126/science.abn5647.
3
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.Claudin18.2 特异性 CAR T 细胞治疗胃肠道肿瘤的 1 期临床试验中期结果
由脾交感神经动员的CD8GZMKCD27CCR7 T细胞通过CCL19阳性内皮细胞加重脑缺血再灌注损伤。
Cell Mol Immunol. 2025 Jul 14. doi: 10.1038/s41423-025-01311-9.
4
Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment.靶向核糖核酸酶-1可释放嵌合抗原受体(CAR)T细胞对骨肉瘤的抗肿瘤活性,并营造促炎性肿瘤微环境。
bioRxiv. 2025 May 23:2025.05.20.650777. doi: 10.1101/2025.05.20.650777.
5
Deep insight into cytokine storm: from pathogenesis to treatment.深入洞察细胞因子风暴:从发病机制到治疗。
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
6
Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.工程化合成信号受体以实现无促红细胞生成素的红细胞生成。
Nat Commun. 2025 Jan 29;16(1):1140. doi: 10.1038/s41467-025-56239-5.
7
ImmunOctoberfest reloaded.免疫十月节重装上阵。
Nat Immunol. 2025 Feb;26(2):165-167. doi: 10.1038/s41590-024-02069-4.
8
Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-β signal.通过逆转转化生长因子-β信号增强免疫抑制性肿瘤微环境中的嵌合抗原受体T细胞功能。
Mol Ther. 2025 Feb 5;33(2):688-702. doi: 10.1016/j.ymthe.2024.12.014. Epub 2024 Dec 13.
9
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.IL-18R 支持的嵌合抗原受体 T 细胞针对癌胚 tenascin C 用于儿科肉瘤和脑肿瘤的免疫治疗。
J Immunother Cancer. 2024 Nov 20;12(11):e009743. doi: 10.1136/jitc-2024-009743.
10
Targeting systemic IL-2 to BCMA CAR-T cells.将全身性白细胞介素-2靶向至靶向B细胞成熟抗原的嵌合抗原受体T细胞(BCMA CAR-T细胞)。
Nat Immunol. 2024 Nov;25(11):1988-1990. doi: 10.1038/s41590-024-01993-9.
Nat Med. 2022 Jun;28(6):1189-1198. doi: 10.1038/s41591-022-01800-8. Epub 2022 May 9.
4
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.长达十年的白血病缓解期与 CD4 CAR T 细胞的持续存在。
Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.
5
Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors.细胞膜锚定和肿瘤靶向的白细胞介素 12(attIL12)-T 细胞疗法用于消除大型异质性实体肿瘤。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003633.
6
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity.瘤内注射明矾连接细胞因子引发强大且更安全的局部和全身抗肿瘤免疫。
Nat Biomed Eng. 2022 Feb;6(2):129-143. doi: 10.1038/s41551-021-00831-9. Epub 2022 Jan 10.
7
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.删除 CAR T 细胞中的 DNMT3A 可防止衰竭并增强抗肿瘤活性。
Sci Transl Med. 2021 Nov 17;13(620):eabh0272. doi: 10.1126/scitranslmed.abh0272.
8
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.一项在恶性胸膜疾病患者中联合抗 PD-1 药物 Pembrolizumab 进行局部间皮素靶向 CAR T 细胞治疗的 I 期临床试验。
Cancer Discov. 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407. Epub 2021 Jul 15.
9
Highly accurate protein structure prediction with AlphaFold.利用 AlphaFold 进行高精度蛋白质结构预测。
Nature. 2021 Aug;596(7873):583-589. doi: 10.1038/s41586-021-03819-2. Epub 2021 Jul 15.
10
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.嵌合抗原受体 T 细胞靶向神经母细胞瘤糖蛋白 2 的肿瘤相关外显子可使其在小鼠中消退。
Cell Rep Med. 2021 Jun 1;2(6):100297. doi: 10.1016/j.xcrm.2021.100297. eCollection 2021 Jun 15.